pf chang bought privat firm profit fall year drug compani known day plenti number moment would arriv best sell drug driven two decad worth profit would lose patent protect succumb competit generic altern without new blockbust replac profit would tumbl pfizer retool lose patent protect best sell drug lipitor last fall go portfolio last week announc plan sell infant nutrit busi sell product powder formula nestl $11 85 billion forpfiz day arriv pfizer profit hit likelipitorandviagra swallow smaller compani 1990s onward immedi successor lipitor best sell drug histori lost patent protect last fall problem punctuat tuesday compani said profit declin 19 percent last quarter larg declin lipitor sale pfizer big big pharma make radic shift one watch close rest industri get smaller last weekth compani announc sell infant nutrit businessto nestl $11 85 billion expect divest profit anim health busi next year time compani isslash much 30 percentof research budget part plan focus promi area likecancerandalzheim disea necessarili smaller per se focus ian read pfizer chief execut said interview tuesday heart biopharmaceut compani focus appli scienc improv peopl qualiti life core determin success pfizer one mani pharmaceut compani race reinvent year alon least 19 drug includ antistrok drug plavix schedul lose patent protect potenti $38 billion lost sale accord analysi barclay drug execut ask face given past decad everyth go right didnt build futur mind said jeremi levin oversaw similar reorgan bristol myer squibb take chief execut teva pharmaceut pfizer skeptic question deci shed profit unit favor doubl riski pharmaceut busi pfizersnutrit unit grew 15 percent anim health 17 percent 2011 pharmaceut sale dip percent pfizer suffer notabl flop last sever year includ thefailur experi cholesterol treatmentthat seen potenti successor lipitor poor sale aninh insulin drugthat compani eventu abandon high risk plan said erik gordon teach busi univ michigan theyr focus dont best track record theyr spin thing pretti well pfizer spent last decad buy big compani 2000 acquir warner lambert right lipitor pfizer co market compani 2003 merg pharmacia ad painkillercelebrexto lineup acquir wyeth 2009 $68 billion deal brought portfolio biolog drug last year pfizer bought king pharmaceut maker pain drug acquisit said turn pfizer frankenstein monster giant stitch togeth scrap smaller compani lurch forward littl purpo think compani sort lost way year wyeth acquisit said catherin arnold analyst credit suiss mr read said agr think broken think spend huge amount money said mr read took chief execut late 2010 jeffrey kindlerresign abrupt werent produc drug need frank seen marketplac analyst said pfizer nutrit deal divestitur anim health busi way tide sharehold undertak substanti chang busi model compani said plan use cash deal buy back stock though studi repeat cast doubt efficaci move corpor pfizer said tuesday repurcha $1 billion stock first quarter expect buy back $5 billion end year compani report earn $1 79 billion last quarter 24 cent share compar $2 22 billion 28 cent share period last year investor seem buy compani strategi far pfizer stock risen near percent last year pfizer stock close $22 78 tuesday 12 cent less percent even compani deci cut research budget plan recommit pharmaceut core struck riski mr gordon michigan busi professor call magic trick magic trick howev major pharmaceut compani also tri question remain success sustain oper invest less less said kenneth kaitin professor director tuft univ center studi drug develop answer tri find new way effici mechan discov develop drug pfizer plan reduc research budget $9 billion 2010 $6 billion $7 billion year close research center britain trim facil groton conn move resourc area closer univ boston cambridg england 2011 compani end 91 project cancel program aim treatingbladd infect exampl well one treat nasal symptom fromallergi compani execut also said lookout smaller acquisit fill gap portfolio expand partnership academ institut mr read said cut would affect area compani priorit cut low probabl success said pfizer anoth lipitor analyst say sever drug seem promi may food drug administr advisori panel consid recommend approv oral pill forrheumatoid arthriti june agenc expect weigh approv eliqui antistrok drug pfizer develop bristol myer squibb corpor strategi pfizer follow path bristol myer 2009 announc plan spin nutrit compani mead johnson focus acquiringsm biotech compani compani sinc fare well despit loss patent protect plavix may 17 long blockbust game work peopl kept play mr gordon said also travel america rebuild fail state order accomplish origin goal 11 artist use cigarett help sooth anxieti ask love thing kill